Hyderabad doctor secures affordable rare disease medication for seven children
A pediatrician in India partnered with accountability organizations to lower the cost of a crucial thyroid hormone treatment for seven children with a rare genetic disorder.
HEROIC BREAKING NEWS, written by our newsroom0 views
Dr Sivaranjani Santosh, a pediatrician based in Hyderabad, has secured affordable access to the medication Tiratricol for seven children living with Allan-Herndon-Dudley syndrome, Telangana Today reported. The physician, working alongside Access to Medicines India, will distribute the life-saving treatment to the patients' families on November 30. [1]
Allan-Herndon-Dudley syndrome is a rare genetic disorder caused by MCT8 deficiency, which impairs thyroid hormone transport into brain cells, according to Telangana Today. The initiative drastically reduced the financial burden on the families by significantly lowering the cost of the drug. [1]
The effort to secure the affordable drug was supported by Access to Medicines India together with the Pharmaceutical Accountability Foundation, Telangana Today reported. Hyderabad serves as the capital of Telangana and operates as a key pharmaceutical center in India. [1][4]
In short
- Dr Sivaranjani Santosh secured affordable Tiratricol treatment for seven children with Allan-Herndon-Dudley syndrome.
- The life-saving medication will be handed over to the families on November 30.
- Access to Medicines India and the Pharmaceutical Accountability Foundation supported the initiative to reduce costs.
Sources
Every paragraph above points to the numbered items it rests on. Read the originals here.
- [1]Hyderabad doctor secures affordable rare disease drug for seven children with AHDSTelangana Today, 2d ago (the report this story comes from)
Background
- [2]Vallabhbhai Patel on Wikipedia
- [3]Hafez al-Assad on Wikipedia
- [4]Hyderabad on Grokipedia
- [5]AIIMS Raipur Surgeons Save Woman's Lung from Rare Parasitic Disease HEROIC BREAKING NEWS, 13d ago
- [6]Alzheimer's research reveals drug that addresses DNA damage and brain inflammation HEROIC BREAKING NEWS, 18d ago
Our newsroom writes these reports with the help of software, from the 6 sources listed and nothing else, and checks them against those sources. Facts can still be wrong or move on; the originals are the record. Spotted a mistake? Write to daniel@monsterkong.com.
Related from HEROIC BREAKING NEWS
Earlier reports of ours on the same people and subjects.
- Vitamin B12 Reverses Development Issues in Model for Rare Genetic DisorderMedical Breakthroughs, 4d ago
- AIIMS Raipur Surgeons Save Woman's Lung from Rare Parasitic DiseaseMedical Breakthroughs, 13d ago
- Hyderabad run highlights neonatal survival on World Prematurity DayMedical Breakthroughs, 5d ago
- IIT Bombay Researchers Develop Low Cost Device to Screen Blood DisordersHumanitarian Tech, 29d ago
- McMaster University and Sartorius Partner to Lower Medication Manufacturing CostsMedical Breakthroughs, 15d ago
More in Medical Breakthroughs
- Arkansas scientists 3D print simulated Moon dust into interlocking building bricks16h ago
- GE HealthCare Foundation Grants Support Global Maternal and Pediatric Care16h ago
- Anthropic researcher uses artificial intelligence to prove Riemann hypothesis16h ago
- Texas Researchers Build Virtual Cell AI to Predict Disease and Treatments1d ago
- Florida Heart Institute Secures Medicare Approval for LVAD Heart Program1d ago
- New daily pill for pancreatic cancer shows promising trial results1d ago
Get the day in one email
Reports like this one, the top news of the last 24 hours, every morning. Free, one email a day; readers can comment under every report.
By signing up you agree to our terms and privacy policy. Unsubscribe any time.


Comments
Loading
Join the conversation
Comments are open to readers of our daily email: the top news of the last 24 hours, every morning, free. Sign up and the comment box opens.
Already on the list? Enter the same address and we will send a sign-in link.
By signing up you agree to our terms and privacy policy. Unsubscribe any time.